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Erythromycin resistance rates were found to be increased, from 7.1 in 1993 to 32.8% in 1997, among
community-acquired Streptococcus pneumoniae isolates from the Siena area of central Italy. Most of the
erythromycin-resistant isolates carried ermAM determinants and were also resistant to josamycin and clin-
damycin, whereas a minority (5.8%) carried mefA determinants and remained susceptible to the latter drugs.
Macrolide and lincosamide antibiotics exhibit strong antimi-
crobial activity against streptococci and are among the drugs
that can be used for chemotherapy of infections caused by
Streptococcus pneumoniae. Macrolide resistance in pneumo-
cocci has been detected at variable rates in different epidemi-
ological settings (see, for instance, references 1, 2, 4, 7, 15, 18,
and 22), with a trend toward increasing resistance being re-
ported by several investigators (4, 6, 9, 21). This is a matter of
major concern, since macrolides are largely prescribed for the
empiric chemotherapy of community-acquired respiratory
tract infections and may be useful in case of intolerance to
b-lactams as well as pneumococcal resistance to other antimi-
crobial agents.
In S. pneumoniae, macrolide resistance can be mediated by
ribosomal modification (8) or active drug efflux (16). The
former mechanism is associated with high-level resistance to
macrolides, lincosamides, and streptogramin B (MLSB-type
resistance pattern) (8), while the latter mechanism is associ-
ated with low-level resistance to 14- and 15-membered-ring
macrolides only (M-type resistance pattern) (16, 19). Both
resistance effectors are encoded by acquired determinants: the
ermAM gene encoding the ribosome-modifying enzyme (8, 20)
and the mefE gene for the efflux system (19). The contributions
of these mechanisms to macrolide resistance in pneumococci
appears to be variable in different epidemiological settings (1,
2, 7, 15, 18, 22), although a molecular analysis of the resistance
determinants was carried out only in a minority of cases (7, 22).
In the work described here we determined the macrolide
and lincosamide susceptibilities of 302 S. pneumoniae isolates
isolated from an area of central Italy over a 5-year period (1993
to 1997) and investigated the resistance determinants carried
by macrolide-resistant isolates.
Pneumococci were randomly selected from among those
that were classified as community acquired and that were cul-
tured at the Laboratory of Clinical Bacteriology of the Institute
of Infectious Diseases, University of Siena, during the period 1
January 1993 to 31 December 1997 from samples from patients
who were residents of the Siena area. Repeated isolates from
the same individual were not included unless the isolations
were separated by a period of at least 1 year. Identification of
pneumococcal isolates was performed by standard procedures
(12). In vitro susceptibility testing was performed by a broth
microdilution method as recommended by the National Com-
mittee for Clinical Laboratory Standards (NCCLS) (10).
Erythromycin and clindamycin were from Sigma Chemical Co.
(St. Louis, Mo.); josamycin was from ICN (Costa Mesa, Calif.).
The breakpoints for susceptibility classification were those
specified by NCCLS (11). S. pneumoniae ATCC 49619 was
used for quality control of susceptibility testing.
Of the 302 pneumococcal isolates, 233 (77.2%) were found
to be susceptible to erythromycin (MICs, #0.015 to 0.06 mg/
ml), josamycin (MICs, 0.06 to 0.25 mg/ml), and clindamycin
(MICs, #0.06 to 0.25 mg/ml), while the remaining 69 (22.8%)
were resistant to erythromycin. Of these, 65 (94.2%) exhibited
high-level resistance to erythromycin (MICs, 128 to .1,024
mg/ml) and also to josamycin (MICs, 16 to .1,024 mg/ml) and
clindamycin (MICs, 512 to .1,024 mg/ml), which is typical of a
constitutive MLSB-type resistance pattern, while the remaining
4 (5.8%) exhibited low-level resistance (MICs, 1 to 8 mg/ml) to
erythromycin only, which is typical of an M-type resistance
pattern. A double-disk diffusion assay (8) confirmed that sus-
ceptibility to josamycin and clindamycin was not influenced by
the presence of erythromycin in the isolates with M-type resis-
tance.
The prevalence of erythromycin-resistant isolates showed a
steady increase during the study period, from 7.1% in 1993 to
32.8% in 1997 (Fig. 1).
The occurrence of ermAM- and mef-related genomic se-
quences was investigated in all the erythromycin-resistant iso-
lates and in 54 (23.2%) randomly selected susceptible isolates
by means of colony blot hybridization with 32P-labeled DNA
probes. Colony blot hybridization was performed as described
previously (13) after an initial exposure (twice for 10 min at
room temperature) of pneumococcal colonies to 1% (wt/vol)
Na-Sarkosyl–1% (wt/vol) sodium deoxycholate–1.5 M NaCl.
With Streptococcus pyogenes and Streptococcus mitis, colony
blotting was performed as described previously (5). The er-
mAM-specific probe was a 764-bp PCR amplicon that contains
the entire ermAM-coding sequence (20). The mef-specific
probes were 346-bp PCR amplicons which contained part of
mefA or mefE, and the amplicons were obtained as described
previously (17). S. pneumoniae 4C1 (ermAM1), S. pyogenes
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1A77 (mefA1), and S. mitis 21A29 (mefE1) were included as
hybridization controls.
The ermAM probe yielded a strong hybridization signal for
all isolates with MLSB-type resistance, while it did not recog-
nize any of the susceptible isolates or isolates with M-type
resistance. The intensity of the hybridization signal was overall
comparable to that obtained with a positive hybridization con-
trol for ermAM (data not shown). The presence of mef-related
sequences was initially investigated with a mefE probe. This
probe yielded a hybridization signal for the four isolates with
M-type resistance, while it did not recognize any of the sus-
ceptible isolates or isolates with MLSB-type resistance. The
hybridization signal, however, was weaker than that obtained
with a positive hybridization control for mefE. By using a mefA
probe, a stronger hybridization signal was obtained for the four
isolates with M-type resistance, and the signal was comparable
to that obtained with a positive hybridization control for mefA
and stronger than that obtained with a positive hybridization
control for mefE (data not shown).
To verify the identities of the mef alleles carried by the four
isolates with M-type resistance, PCR was carried out with
primers MEFA-up (59-GACCAAAAGCCACATTGTGGA)
and MEFA-dn (59-CCTCCTGTCTATAATCGCATG), which
were designed on the basis of sequences that flank the mefA
gene from S. pyogenes 02C1064 (3), by using the following
cycling conditions: 94°C for 30 s, 58°C for 60 s, and 70°C for
80 s, which were repeated for 40 cycles. In all cases an am-
plimer of the expected size (1,431 bp) was obtained. Restric-
tion analysis of the amplimers with AvaII, BamHI, ClaI,
HindIII, and NheI yielded in all cases a profile consistent with
the sequence of mefA (with AvaII, products of 283, 419, and
729 bp; with BamHI, products of 223 and 1,208 bp; with ClaI,
products of 620 and 811 bp; with HindIII, products of 437 and
994 bp; with NheI, a product of 1,431 bp) (3) but not with that
of mefE (with AvaII, products of 283, 372, and 776 bp; with
BamHI, a product of 1,431 bp; with ClaI, a product of 1,431 bp;
with HindIII, a product of 1,431 bp; with NheI, products of 525
and 906 bp) (19).
Concluding remarks. Similar to what has been observed
elsewhere (4, 6, 9, 21), the prevalence of macrolide-resistant
pneumococci has also recently undergone a substantial in-
crease in the Siena area of central Italy, with macrolide-resis-
tant pneumococci making up nearly one-third of the commu-
nity-acquired isolates in 1997. A similar situation is probably
consequent to an increased selective pressure generated by
increased prescriptions of macrolides in community medicine,
as has previously been demonstrated for S. pyogenes (14).
The results of this study revealed that, in our region, the
most prevalent macrolide resistance phenotype among pneu-
mococcal isolates is the MLSB type and that the relevant in-
crease in the number of macrolide-resistant pneumococci ob-
served during the study period was virtually completely a result
of isolates that carry ermAM determinants. Isolates that have
M-type resistance and that carry mef determinants have ap-
peared only since 1995 and remain uncommon. A similar pat-
tern of macrolide resistance determinants in pneumococci has
also been observed in Spain (1), although it is different from
those encountered in other countries where lower relative
rates of isolates with MLSB-type resistance have been observed
(7, 22). The relative prevalence of the two macrolide resistance
mechanisms in pneumococci therefore exhibits remarkable
geographical heterogeneity. This essentially results from large
variations in the absolute rates of occurrence of isolates with
MLSB-type resistance, whereas the prevalence of pneumococci
with M-type resistance showed an overall low variability (0.45
to 1.6%) in different epidemiological settings (1, 7, 22; this
study), suggesting that the erm determinants play a major role
in the geographical and temporal variability in macrolide re-
sistance rates among pneumococci. Molecular analysis also
showed that all the pneumococci with M-type resistance en-
countered in this study apparently carried a mefA determinant,
revealing that not only mefE but also mefA can be acquired by
S. pneumoniae, resulting in an M-type resistance phenotype.
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